Cancer type | miRNA target and its role in cancer | Delivery system to modulate the miRNA in vivo* | Reference |
---|---|---|---|
Breast cancer | miR-34a – Tumor suppressor | Cationic liposomes | [109] |
Glioblastoma | miR-145 – Tumor suppressor | Adenoviruses | [110] |
Glioblastoma | miR-221-222 – Oncogene | Adenoviruses | [111] |
Glioblastoma Multiforme (GBM) | miR-9 – promote expression of P-gp (a multidrug resistance efflux transporter) | - Mesenchymal stem cell-derived exosomes | [112] |
- To deliver anti-miR-9 to temozolomide-resistant GBM to reduce P-gp expression for resistance reversal | |||
Hepatocellular carcinoma | miR-26 – Tumor suppressor | Adenoviruses | [113] |
Lung cancer | let-7 – Tumor suppressor | Adenoviruses | [114] |
Lung cancer | miR-34a – Tumor suppressor | Cationic liposomes | [115] |
Lymphoma | miR-155 – Oncogene | Polymer-based nanoparticles | [116] |
Medulloblastoma | miR-17 ~ 92 cluster family – Sonic Hedgehog signaling | 8-mer seed-targeting locked nucleic acid (LNA)-modified anti-miR oligonucleotides (nude mice) | [117] |
Pancreatic cancer | miR-21 – Oncogene | Lentiviruses | [118] |